| Dr Edward Stanley Sawicki, MD | |
|
1703 Main St, Willimantic, CT 06226-1162 | |
| (860) 456-1781 | |
| (860) 450-1660 |
| Full Name | Dr Edward Stanley Sawicki |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 1703 Main St, Willimantic, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013916097 | NPI | - | NPPES |
| 16392 | Other | CT | CT LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 1163922 (Connecticut) | Primary |
| Entity Name | Hartford Healthcare Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043561301 PECOS PAC ID: 1153573902 Enrollment ID: O20121201000007 |
News Archive
Indiana Governor Mike Pence (R) signed into law Senate Bill 233 yesterday, which authorizes licensure for anesthesiologist assistants. The American Society of Anesthesiologists and the Indiana Society of Anesthesiologists applaud this action, which will make the services of anesthesiologist assistants available to Indiana patients.
Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.
Lax requirements for both caregivers and patients, along with poor state and federal oversight, have made the rapidly growing Medicaid personal-care programs an increasingly lucrative target for fraud, according to a federal report scheduled for release Thursday.
IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.
A new study by researchers at the City University of Hong Kong examined the efficacy of non-pharmaceutical interventions (NPIs) on controlling the coronavirus disease 2019 (COVID-19) pandemic, the illness SARS-CoV-2 causes.
› Verified 8 days ago
| Entity Name | Hartford Healthcare Medical Group Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023584216 PECOS PAC ID: 3173866241 Enrollment ID: O20190514001441 |
News Archive
Indiana Governor Mike Pence (R) signed into law Senate Bill 233 yesterday, which authorizes licensure for anesthesiologist assistants. The American Society of Anesthesiologists and the Indiana Society of Anesthesiologists applaud this action, which will make the services of anesthesiologist assistants available to Indiana patients.
Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.
Lax requirements for both caregivers and patients, along with poor state and federal oversight, have made the rapidly growing Medicaid personal-care programs an increasingly lucrative target for fraud, according to a federal report scheduled for release Thursday.
IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.
A new study by researchers at the City University of Hong Kong examined the efficacy of non-pharmaceutical interventions (NPIs) on controlling the coronavirus disease 2019 (COVID-19) pandemic, the illness SARS-CoV-2 causes.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edward Stanley Sawicki, MD 1290 Silas Deane Hwy, Hhc Cvo Enrollment, Wethersfield, CT 06109-4337 Ph: (860) 972-6970 | Dr Edward Stanley Sawicki, MD 1703 Main St, Willimantic, CT 06226-1162 Ph: (860) 456-1781 |
News Archive
Indiana Governor Mike Pence (R) signed into law Senate Bill 233 yesterday, which authorizes licensure for anesthesiologist assistants. The American Society of Anesthesiologists and the Indiana Society of Anesthesiologists applaud this action, which will make the services of anesthesiologist assistants available to Indiana patients.
Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.
Lax requirements for both caregivers and patients, along with poor state and federal oversight, have made the rapidly growing Medicaid personal-care programs an increasingly lucrative target for fraud, according to a federal report scheduled for release Thursday.
IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.
A new study by researchers at the City University of Hong Kong examined the efficacy of non-pharmaceutical interventions (NPIs) on controlling the coronavirus disease 2019 (COVID-19) pandemic, the illness SARS-CoV-2 causes.
› Verified 8 days ago
Marlene Schwartz, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 112 Mansfield Ave, Pulmonary Disease Division, Hatch Wing, Willimantic, CT 06226 Phone: 860-456-7279 Fax: 860-450-0269 | |
Dr. Kipp W. Spencer, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 40 Mansfield Ave, Willimantic, CT 06226 Phone: 860-450-7471 | |
Gregory Haman, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 Founders St Ste 100, Willimantic, CT 06226 Phone: 860-423-9764 | |
Samer T Morcos, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 112 Mansfield Ave, Willimantic, CT 06226 Phone: 860-456-6713 Fax: 860-456-6838 | |
Nagireddy Kamireddy, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 96 Mansfield Ave, Willimantic, CT 06226 Phone: 860-450-7583 | |
Dr. Stephen J Leach, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 37 Ivan Hill St, Willimantic, CT 06226 Phone: 860-423-9764 Fax: 860-423-9866 |